Regencell Bioscience
RGC
NASDAQ
IPO2021
about RGC
Regencell Bioscience is an early-stage bioscience company focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for neurocognitive disorders, particularly ADHD and Autism Spectrum Disorder (ASD), and certain infectious diseases.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $62.00 | $69.00 | $34.00 | $26.1B | 3.38M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| +$0.07 | 47.93 | 8.40 | 3.14% | 1.59% | 2.30% |